Insulin Resistance and Inflammation in the Early Phase of Type 2 Diabetes: Potential for Therapeutic Intervention

References

• King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–1431
   PubMed Web of Science ®Google Scholar
• Isomaa B., Almgren P., Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689
   PubMed Web of Science ®Google Scholar
• Reaven G. M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607
   PubMed Web of Science ®Google Scholar
• Kylin E. Studien über das Hypertonie‐Hyperglykamie‐Hyperurikamiesyndrom. Zentralblatt für Innere Medizin 1923; 44: 105–127
   Google Scholar
• Bonora E., Kiechl S., Willeit J. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643–1649
   PubMed Web of Science ®Google Scholar
• Hanson R. L., Imperatore G., Bennett P. H., Knowler W. C. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 2002; 51: 3120–3127
   PubMed Web of Science ®Google Scholar
• Pereira M. A., Kartashov A. I., Ebbeling C. B., Van horn L., Slattery M. L., Jacobs dr D. R Jr., Ludwig D. S. Fast‐food habits, weight gain, and insulin resistance (the CARDIA study): 15‐year prospective analysis. Lancet 2005; 365: 36–42
   PubMed Web of Science ®Google Scholar
• Dunstan D. W., Zimmet P. Z., Welborn T. A. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829–834
   PubMed Web of Science ®Google Scholar
• Accili D. Perspectives in Diabetes. The Struggle for Mastery in Insulin Action: From Triumvirate to Republic. Diabetes 2004; 53: 1633–1642
   PubMed Web of Science ®Google Scholar
• Pickup J. C., Mattock M. B., Chusney G. D., Burt D. NIDDM as a disease of the innate immune system: association of acute‐phase reactants and IL‐6 with metabolic syndrome X. Diabetologia 1997; 40: 1286–1292
   PubMed Web of Science ®Google Scholar
• Pradhan A. D., Manson J. E., Rifai N. C‐reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327–334
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Buring J. E. C‐reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843
   PubMed Web of Science ®Google Scholar
• Han T. S., Sattar N., Williams K. Prospective study of reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016–2021
   PubMed Web of Science ®Google Scholar
• Freeman D. J., Norrie J., Caslake M. J. C‐reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596–1600
   PubMed Web of Science ®Google Scholar
• Duncan B. B., Schmidt M. I., Pankow J. S. Low‐grade systemic inflammation and the development of type 2 diabetes. Diabetes 2003; 52: 1799–1805
   PubMed Web of Science ®Google Scholar
• Verma S., Kuliszewski M. A., Li S. H. C‐reactive protein attenuates endothelial progenitor cell survival, differentiation, and function. Circulation 2004; 109: 2058–2067
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Wilson P. W., Grundy S. M. Should C‐reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 2004; 109: 2818–2825
   PubMed Web of Science ®Google Scholar
• The Diabetes Prevention Program Research Group. Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150–1156
   PubMed Web of Science ®Google Scholar
• Schernthaner G. Cardiovascular mortality and morbidity in type‐2 diabetes mellitus. Diabetes Research and Clinical Practise 1996; 31 Suppl: S3–S13
   PubMedGoogle Scholar
• Haffner S. M., Mykkanen L., Festa A. Insulin‐resistant prediabetic subjects have more atherogenic risk factors than insulin‐sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975–980
   PubMed Web of Science ®Google Scholar
• Festa A., D'agostino r R Jr., Howard G. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 2000; 102: 42–47
   PubMed Web of Science ®Google Scholar
• Haffner S. M., Greenberg A. S., Weston W. M. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679–684
   PubMed Web of Science ®Google Scholar
• Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4–7
   PubMed Web of Science ®Google Scholar
• Fernandez‐real J. M., Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278–301
   PubMed Web of Science ®Google Scholar
• Sjöholm A., Nyström T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610–612
   PubMed Web of Science ®Google Scholar
• Devaraj S., Rosenson R. S., Jialal I. Metabolic syndrome: an appraisal of the pro‐inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33: 431–453
   PubMed Web of Science ®Google Scholar
• Trayhurn P., Wood I. S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–355
   PubMed Web of Science ®Google Scholar
• Ouchi N., Kihara S., Arita Y. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF‐kB signaling through a cAMP‐dependent pathway. Circulation 2000; 102: 1296–1301
   PubMed Web of Science ®Google Scholar
• Hotta K., Funahashi T., Arita Y. Plasma concentrations of a novel, adipose‐specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599
   PubMed Web of Science ®Google Scholar
• Weyer C., Funahashi T., Tanaka S. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935
   PubMed Web of Science ®Google Scholar
• Duncan B. B., Schmidt M. I., Pankow J. S. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2004; 53: 2473–2478
   PubMed Web of Science ®Google Scholar
• Lindsay R. S., Funahashi T., Hanson R. L. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57–58
   PubMed Web of Science ®Google Scholar
• Snehalatha C., Mukesh B., Simon M. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 2003; 26: 3226–3229
   PubMed Web of Science ®Google Scholar
• Spranger J., Kroke A., Mohlig M. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226–228
   PubMed Web of Science ®Google Scholar
• Krakoff J., Funahashi T., Stehouwer C. D. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745–1751
   PubMed Web of Science ®Google Scholar
• Yu J. G., Javorschi S., Hevener A. L. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968–2974
   PubMed Web of Science ®Google Scholar
• Kang E. S., Park S. Y., Kim H. J., Ahn C. W., Nam M., Cha B. S., Lim S. K., Kim K. R., Lee H. C. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005; 28: 1139–1144
   PubMed Web of Science ®Google Scholar
• Debril M. B., Renaud J. P., Fajas L. The pleiotropic functions of peroxisome proliferator‐activated receptor. J Mol Med 2001; 79: 30–47
   PubMed Web of Science ®Google Scholar
• Desvergne B., Wahli W. Peroxisome proliferator‐activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–688
   PubMed Web of Science ®Google Scholar
• Yoshimoto T., Naruse M., Nishikawa M. Antihypertensive and vasculo‐ and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997; 272: E989–E996
   PubMed Web of Science ®Google Scholar
• Smith U. Thiazolidinedione‐induced effects beyond glycaemic control. Br J Diabetes Vasc Dis 2002; 2 (suppl 1): S24–S27
   Google Scholar
• Bennett S. M., Agrawal A., Elasha H., Heise M., Jones N. P., Walker M., Wilding J. P. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004; 21: 415–422
   PubMed Web of Science ®Google Scholar
• Chiquette E., Ramirez G., Defronzo R. A meta‐analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004; 164: 2097–2104
   PubMed Web of Science ®Google Scholar
• Langenfeld M. R., Forst T., Hohberg C., Kann P., Lubben G., Konrad T., Fullert S. D., Sachara C., Pfutzner A. Pioglitazone decreases carotid intima‐media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525–2531
   PubMed Web of Science ®Google Scholar
• Choi D., Kim S. K., Choi S. H., Ko Y. G., Ahn C. W., Jang Y., Lim S. K., Lee H. C., Cha B. S. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654–60
   PubMed Web of Science ®Google Scholar
• Reaven G. M. The Insulin Resistance Syndrome: Definition and Dietary Approaches to Treatment. Annu Rev Nutr 2005; 25: 17.1–17.16
   Web of Science ®Google Scholar
• Hu G., Jousilahti P., Barengo N. C., Qiao Q., Lakka T. A., Tuomilehto J. Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care 2005; 28: 799–805
   PubMed Web of Science ®Google Scholar
• Schernthaner G., Matthews D. R., Charbonnel B., Hanefeld M., Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double‐blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068–6076
   PubMed Web of Science ®Google Scholar
• Charbonnel B. H., Matthews D. R., Schernthaner G., Hanefeld M., Brunetti P. A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallelgroup comparison trial. Diabet Med 2005; 22: 399–405
   PubMed Web of Science ®Google Scholar
• Hanefeld M., Brunetti P., Schernthaner G. H., Matthews D. R., Charbonnel B. H. One‐year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141–147
   PubMed Web of Science ®Google Scholar
• Matthews D. R., Charbonnel B. H., Hanefeld M., Brunetti P., Schernthaner G. Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21: 167–174
   PubMed Web of Science ®Google Scholar
• Ceriello A., Johns D., Widel M., Eckland D. J., Gilmore K. J., Tan M. H. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28: 266–272
   PubMed Web of Science ®Google Scholar
• Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., Mandarino L. J., Defronzo R. A. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784–2791
   PubMed Web of Science ®Google Scholar
• Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L. J., Pratipanawatr W., Glass L., Cersosimo E., Miyazaki Y., Defronzo R. A. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364–1370
   PubMed Web of Science ®Google Scholar
• Tiikkainen M., Hakkinen A. M., Korsheninnikova E., Nyman T., Makimattila S., Yki‐jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169–2176
   PubMed Web of Science ®Google Scholar
• Retnakaran R., Hanley A. J., Raif N., Hirning C. R., Connelly P. W., Sermer M., Kahn S. E., Zinman B. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia 2005; 48: 993–1001
   PubMed Web of Science ®Google Scholar
• Charbonnel B., Schernthaner G., Brunetti P., Matthews D. R., Urquhart R., Tan M. H., Hanefeld M. Long‐term efficacy and tolerability of add‐on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia, 2005 in press
   Web of Science ®Google Scholar
• Nesto R. W., Bell D., Bonow R. O., Fonseca V., Grundy S. M., Horton E. S., Le winter M., Porte D., Semenkovich C. F., Smith S., Young L. H., Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256–263
   PubMed Web of Science ®Google Scholar
• Masoudi F. A., Inzucchi S. E., Wang Y., Havranek E. P., Foody J. M., Krumholz H. M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583–590
   PubMed Web of Science ®Google Scholar
• Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–923
   PubMed Web of Science ®Google Scholar
• Belcher G., Schernthaner G. Changes in liver tests during one‐year treatment of patients with type 2 diabetes with pioglitazone, metformin, or gliclazide. Diabetic Medicine, 2005 in press
   Google Scholar
• Charbonnel B., Dormandy J., Erdmann E., Massi‐benedetti M., Skene A. PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647–1653
   PubMed Web of Science ®Google Scholar
• Schernthaner G. Progress in the prevention of type 2 Diabetes. Wien.Klin.Wochenschr 2003; 115: 745–757
   PubMed Web of Science ®Google Scholar
• Pan X. R., Li G. W., Hu Y. H., Wang J. X., Yang W. Y., An Z. X., Hu Z. X., Lin J., Xiao J. Z., Cao H. B., Liu P. A., Jiang X. G., Jiang Y. Y., Wang J. P., Zheng H., Zhang H., Bennett P. H., Howard B. V. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537–544
   PubMed Web of Science ®Google Scholar
• Tuomilehto J., Lindström J., Eriksson J. G., Valle T. T., Hämäläinen H., Ilanne‐parikka P. Prevention of type‐2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350
   PubMed Web of Science ®Google Scholar
• Knowler W. C., Barrett‐connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403
   PubMed Web of Science ®Google Scholar
• Chiasson J. L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type‐2 diabetes mellitus: the STOP‐NIDDM randomised trial. Lancet 2002; 359: 2072–2077
   PubMed Web of Science ®Google Scholar
• Hensrud D. D. Dietary treatment and long‐term weight loss and maintenance in type 2 diabetes. Obes Res 2001; Suppl 4: 348S–353S
   Google Scholar
• Sjostrom L., Lindroos A. K., Peltonen M. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683–2693
   PubMed Web of Science ®Google Scholar
• Buchwald H., Avidor Y., Braunwald E. Bariatric surgery: a systematic review and meta‐analysis. JAMA 2004; 292: 1724–1737
   PubMed Web of Science ®Google Scholar
• Kopp H. P., Kopp C. W., Festa A. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042–7
   PubMed Web of Science ®Google Scholar
• Christou N. V., Sampalis J. S., Liberman M. Surgery decreases long‐term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416–23
   PubMed Web of Science ®Google Scholar
• Kopp C. W., Kopp H. P., Steiner S. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003; 11: 950–956
   PubMedGoogle Scholar
• Krzyzanowska K., Mittermayer F., Kopp H. P. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol.Metab 2004; 89: 6277–6281
   PubMed Web of Science ®Google Scholar
• Kopp H. P., Spranger J., Möhlig M., Krzyzanowska K., Pfeiffer A. F. H. Schernthaner G Effect of weight loss on plasma levels of adiponectin in association with markers of chronic subclinical inflammation and the insulin resistance syndrome in obese subjects. Internat. J. Obes, 2005 in press
   Google Scholar